Advertisement
Screener

REPLIGEN CORP (RGEN) Goodwill, Foreign Currency Translation Gain (Loss)

3.0 / 5 stars · 72/120 Roast Me

REPLIGEN CORP Goodwill, Foreign Currency Translation Gain (Loss)

REPLIGEN CORP (RGEN) reported Goodwill, Foreign Currency Translation Gain (Loss) of $9.51 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.

Financial Statements › Income Statement › Other Income

us-gaap:GoodwillForeignCurrencyTranslationGainLoss · last filed 2026-07-29

  • REPLIGEN CORP goodwill, foreign currency translation gain (loss) for the quarter ending 2026-06-30 was $2.69M.
  • REPLIGEN CORP goodwill, foreign currency translation gain (loss) for the quarter ending 2026-03-31 was $6.82M.
  • REPLIGEN CORP goodwill, foreign currency translation gain (loss) for the quarter ending 2025-12-31 was -$1.55M, a 141.64% decline year-over-year.
  • REPLIGEN CORP goodwill, foreign currency translation gain (loss) for the quarter ending 2025-09-30 was $1.27M.
  • REPLIGEN CORP goodwill, foreign currency translation gain (loss) for fiscal 2025 was -$33.40M, a 1152.24% decline from fiscal 2024.
  • REPLIGEN CORP goodwill, foreign currency translation gain (loss) for fiscal 2024 was $3.17M.
  • REPLIGEN CORP goodwill, foreign currency translation gain (loss) for fiscal 2023 was -$1.51M, a 155.14% decline from fiscal 2022.
  • REPLIGEN CORP goodwill, foreign currency translation gain (loss) for fiscal 2022 was $2.73M.
Period endGoodwill, Foreign Currency Translation Gain (Loss) 3 monthGoodwill, Foreign Currency Translation Gain (Loss) 6 monthGoodwill, Foreign Currency Translation Gain (Loss) 9 monthGoodwill, Foreign Currency Translation Gain (Loss) 12 monthGoodwill, Foreign Currency Translation Gain (Loss) 12 month as first filed
2026-06-30$2.69M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-07-29
$9.51M
10-Q · filed 2026-07-29
$7.96M
derived: sum of 3 quarters · filed 2026-07-29
$9.23M
derived: sum of 4 quarters · filed 2026-07-29
2026-03-31$6.82M
10-Q · filed 2026-05-06
$5.27M
derived: sum of 2 quarters · filed 2026-05-06
$6.54M
derived: sum of 3 quarters · filed 2026-05-06
-$25.29M
derived: sum of 4 quarters · filed 2026-05-06
2025-12-31-$1.55M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
-$279.00K
derived: sum of 2 quarters · filed 2026-02-26
-$32.11M
derived: sum of 3 quarters · filed 2026-02-26
-$33.40M
10-K · filed 2026-02-26
2025-09-30$1.27M
derived: 10-K 12 month − 3 quarters · filed 2026-02-26
-$30.56M
derived: sum of 2 quarters · filed 2026-02-26
-$31.84M
10-Q · filed 2025-11-04
-$28.11M
derived: sum of 4 quarters · filed 2026-02-26
2025-06-30-$31.84M
10-Q · filed 2025-08-07
-$33.12M
derived: sum of 2 quarters · filed 2025-08-07
-$29.39M
derived: sum of 3 quarters · filed 2026-02-26
-$31.40M
derived: sum of 4 quarters · filed 2026-02-26
2025-03-31-$1.28M
10-Q · filed 2025-08-07
$2.45M
derived: sum of 2 quarters · filed 2026-02-26
$439.00K
derived: sum of 3 quarters · filed 2026-02-26
$789.00K
derived: sum of 4 quarters · filed 2026-02-26
2024-12-31$3.73M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26
$1.72M
derived: sum of 2 quarters · filed 2026-02-26
$2.07M
derived: sum of 3 quarters · filed 2026-02-26
$3.17M
10-K · filed 2026-02-26
2024-09-30-$2.01M
derived: 10-Q 9 month − 10-Q/A 6 month · filed 2024-11-18
-$1.66M
derived: sum of 2 quarters · filed 2024-11-18
-$556.00K
10-Q · filed 2024-11-18
-$2.65M
derived: sum of 4 quarters · filed 2025-03-14
2024-06-30$350.00K
derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18
$1.45M
10-Q/A · filed 2024-11-18
-$639.00K
derived: sum of 3 quarters · filed 2025-03-14
$763.00K
derived: sum of 4 quarters · filed 2025-03-14
2024-03-31$1.10M
10-Q/A · filed 2024-11-18
-$989.00K
derived: sum of 2 quarters · filed 2025-03-14
$413.00K
derived: sum of 3 quarters · filed 2025-03-14
$381.00K
derived: sum of 4 quarters · filed 2025-03-14
2023-12-31-$2.09M
derived: 10-K 12 month − 10-Q/A 9 month · filed 2025-03-14
-$688.00K
derived: sum of 2 quarters · filed 2025-03-14
-$720.00K
derived: sum of 3 quarters · filed 2025-03-14
-$1.51M
10-K · filed 2025-03-14
2023-09-30$1.40M
derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2024-11-18
$1.37M
derived: sum of 2 quarters · filed 2024-11-18
$582.00K
10-Q/A · filed 2024-11-18
-$3.50M
derived: sum of 4 quarters · filed 2024-11-18
2023-06-30-$32.00K
derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2024-11-18
-$820.00K
10-Q/A · filed 2024-11-18
-$4.90M
derived: sum of 3 quarters · filed 2024-11-18
-$1.96M
derived: sum of 4 quarters · filed 2024-11-18
2023-03-31-$788.00K
10-Q/A · filed 2024-11-18
-$4.87M
derived: sum of 2 quarters · filed 2024-11-18
-$1.93M
derived: sum of 3 quarters · filed 2024-11-18
$1.07M
derived: sum of 4 quarters · filed 2024-11-18
2022-12-31-$4.08M
derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-11-18
-$1.14M
derived: sum of 2 quarters · filed 2024-11-18
$1.86M
derived: sum of 3 quarters · filed 2024-11-18
$2.73M
10-K/A · filed 2024-11-18
-$2.73M
10-K · filed 2023-02-22
2022-09-30$2.94M
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-01
$5.93M
derived: sum of 2 quarters · filed 2022-11-01
$6.81M
10-Q · filed 2022-11-01
$2.36M
derived: sum of 4 quarters · filed 2023-02-22
2022-06-30$3.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-02
$3.87M
10-Q · filed 2022-08-02
-$574.00K
derived: sum of 3 quarters · filed 2023-02-22
$376.00K
derived: sum of 4 quarters · filed 2023-02-22
2022-03-31$878.00K
10-Q · filed 2022-04-27
-$3.57M
derived: sum of 2 quarters · filed 2023-02-22
-$2.62M
derived: sum of 3 quarters · filed 2023-02-22
-$2.85M
derived: sum of 4 quarters · filed 2023-02-22
2021-12-31-$4.45M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-22
-$3.50M
derived: sum of 2 quarters · filed 2023-02-22
-$3.72M
derived: sum of 3 quarters · filed 2023-02-22
-$2.92M
10-K · filed 2023-02-22
2021-09-30$950.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-28
$724.00K
derived: sum of 2 quarters · filed 2021-10-28
$1.53M
10-Q · filed 2021-10-28
$723.00K
derived: sum of 4 quarters · filed 2022-02-17
2021-06-30-$226.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-07-27
$581.00K
10-Q · filed 2021-07-27
-$227.00K
derived: sum of 3 quarters · filed 2022-02-17
-$972.00K
derived: sum of 4 quarters · filed 2022-02-17
2021-03-31$807.00K
10-Q · filed 2021-05-04
-$1.00K
derived: sum of 2 quarters · filed 2022-02-17
-$746.00K
derived: sum of 3 quarters · filed 2022-02-17
-$1.09M
derived: sum of 4 quarters · filed 2022-02-17
2020-12-31-$808.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-17
-$1.55M
derived: sum of 2 quarters · filed 2022-02-17
-$1.90M
derived: sum of 3 quarters · filed 2022-02-17
-$1.57M
10-K · filed 2022-02-17
2020-09-30-$745.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
-$1.09M
derived: sum of 2 quarters · filed 2020-11-05
-$764.00K
10-Q · filed 2020-11-05
-$1.21M
derived: sum of 4 quarters · filed 2021-02-24
2020-06-30-$343.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-07-30
-$19.00K
10-Q · filed 2020-07-30
-$469.00K
derived: sum of 3 quarters · filed 2021-02-24
$218.00K
derived: sum of 4 quarters · filed 2021-02-24
2020-03-31$324.00K
10-Q · filed 2020-05-06
-$126.00K
derived: sum of 2 quarters · filed 2021-02-24
$561.00K
derived: sum of 3 quarters · filed 2021-02-24
$327.00K
derived: sum of 4 quarters · filed 2021-02-24
2019-12-31-$450.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24
$237.00K
derived: sum of 2 quarters · filed 2021-02-24
$3.00K
derived: sum of 3 quarters · filed 2021-02-24
$343.00K
10-K · filed 2021-02-24
2019-09-30$687.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-10-31
$453.00K
derived: sum of 2 quarters · filed 2019-10-31
$793.00K
10-Q · filed 2019-10-31
2019-06-30-$234.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01
$106.00K
10-Q · filed 2019-08-01
2019-03-31$340.00K
10-Q · filed 2019-05-09
2018-12-31$801.00K
10-K · filed 2020-02-26
2017-12-31-$2.18M
10-K · filed 2019-03-01

Similar stocks

Stock NameCountryMarket CapPE Ratio
Krystal Biotech, Inc. (KRYS)United States$10.210B45.56
BIO-TECHNE Corp (TECH)United States$11.379B74.68
Twist Bioscience Corp (TWST)United States$11.540B-47.21
Kymera Therapeutics, Inc. (KYMR)United States$9.631B-31.69
ImmunityBio, Inc. (IBRX)United States$9.157B-9.29
Vaxcyte, Inc. (PCVX)United States$8.466B-7.91
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
EXELIXIS, INC. (EXEL)United States$14.358B16.15
Immunovant, Inc. (IMVT)United States$7.028B-14.78